Arbeitsgemeinschaft Medikamentöse Tumortherapie - Developmental Therapeutics Review - Q4 2010

Global Markets Direct, December 2010, Pages: 38

Arbeitsgemeinschaft Medikamentöse Tumortherapie – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Arbeitsgemeinschaft Medikamentöse Tumortherapie - Developmental Therapeutics Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Arbeitsgemeinschaft Medikamentöse Tumortherapie - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Arbeitsgemeinschaft Medikamentöse Tumortherapie human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Arbeitsgemeinschaft Medikamentöse Tumortherapie with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Arbeitsgemeinschaft Medikamentöse Tumortherapie’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Arbeitsgemeinschaft Medikamentöse Tumortherapie’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Arbeitsgemeinschaft Medikamentöse Tumortherapie in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Arbeitsgemeinschaft Medikamentöse Tumortherapie’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Arbeitsgemeinschaft Medikamentöse Tumortherapie.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Arbeitsgemeinschaft Medikamentöse Tumortherapie and identify potential opportunities in those areas.

List of Tables
List of Figures
Arbeitsgemeinschaft Medikamentöse Tumortherapie Snapshot
Key Information
Key Facts
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Research and Development Overview
Key Therapeutic Areas
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Pipeline Products Glance
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Arbeitsgemeinschaft Medikamentöse Tumortherapie Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Drug Profiles
Rituximab
Product Description
Mechanism of Action
R&D Progress
Bendamustine + Alemtuzumab
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Bevacizumab + Irinotecan + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Eloxatin + Camptosar + Avastin + Taxotere
Product Description
Mechanism of Action
R&D Progress
Fludarabine phosphate + Alemtuzumab
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Vorinostat + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
R-COMP
Product Description
Mechanism of Action
R&D Progress
Rituximab + 2-CdA
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cladribine
Product Description
Mechanism of Action
R&D Progress
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Pipeline Analysis
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Pipeline Products by Therapeutic Class
Arbeitsgemeinschaft Medikamentöse Tumortherapie Pipeline Products By Target
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Pipeline Products by Route of Administration
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Pipeline Products by Molecule Type
Arbeitsgemeinschaft Medikamentöse Tumortherapie – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• International Military and Government Helicopter Survey
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles